CASTLE BIOSCIENCES, INC. Deferred Costs
CASTLE BIOSCIENCES, INC. (CSTL) had Deferred Costs of $1.03 million as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredCostsCurrentAndNoncurrent · last filed 2022-05-09
- 2022-03-31: Deferred Costs $1.03M.
- 2021-03-31: Deferred Costs $0.00.
| Period end | Deferred Costs |
|---|---|
| 2022-03-31 | $1.03M 10-Q · filed 2022-05-09 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |